Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

NCT04805307 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)
Pancreatic Cancer

Interventions

DRUG: CMG901

Sponsor

Keymed Biosciences Co.Ltd